AtriCure (NASDAQ:ATRC) Issues Quarterly Earnings Results

AtriCure (NASDAQ:ATRC - Get Free Report) released its quarterly earnings data on Tuesday. The medical device company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11, Zacks reports. The business had revenue of $123.62 million for the quarter, compared to analyst estimates of $122.92 million. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. AtriCure's revenue was up 13.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.28) earnings per share. AtriCure updated its FY 2025 guidance to -0.550--0.500 EPS.

AtriCure Stock Up 3.1 %

ATRC traded up $0.91 during midday trading on Friday, hitting $30.20. The company had a trading volume of 262,958 shares, compared to its average volume of 661,946. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -31.85 and a beta of 1.65. The stock's 50 day moving average price is $33.76 and its 200 day moving average price is $34.67. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. AtriCure has a 52 week low of $18.94 and a 52 week high of $43.11.

Analyst Ratings Changes

ATRC has been the subject of several research reports. Canaccord Genuity Group dropped their price objective on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research note on Friday, March 28th. JMP Securities restated a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a report on Wednesday. JPMorgan Chase & Co. cut their target price on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, March 27th. Needham & Company LLC decreased their price target on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Piper Sandler boosted their price objective on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, AtriCure has a consensus rating of "Moderate Buy" and a consensus target price of $50.67.

Insider Activity at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the transaction, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is currently owned by corporate insiders.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.